AbbVie Announces Global Resolution Of HUMIRA Patent Disputes With Fresenius Kabi; Agreements Provide Non-Exclusive License To Fresenius Kabi For HUMIRA-Related IP In US Effective Sept. 2023, Fresenius Acknowledges Abbvie's Intellectual Priperty For Humira